Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Reata Pharmaceuticals Inc (RETA) Ord Class A

Sell:$91.48 Buy:$92.00 Change: $2.02 (2.26%)
NASDAQ:1.08%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$91.48
Buy:$92.00
Change: $2.02 (2.26%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$91.48
Buy:$92.00
Change: $2.02 (2.26%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Contact details

Address:
2801 Gateway Dr Ste 150
IRVING
75063
United States
Telephone:
+1 (972) 8652206
Website:
https://reatapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RETA
ISIN:
US75615P1030
Market cap:
$2.69 billion
Shares in issue:
30.06 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • J. Warren Huff
    Chairman of the Board, President, Chief Executive Officer
  • Jason Wilson
    Chief Financial Officer and Vice President, Strategy
  • Dawn Bir
    Vice President, Chief Commercial Officer
  • Colin Meyer
    Chief Medical Officer and Vice President, Product Development
  • Keith Ward
    Vice President, Chief Development Officer
  • Michael Wortley
    Vice President, Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.